National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 65698 [2012-26603]

Download as PDF 65698 Federal Register / Vol. 77, No. 210 / Tuesday, October 30, 2012 / Notices Dated: October 24, 2012. Mary K. Wakefield, Administrator. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. wreier-aviles on DSK7SPTVN1PROD with NOTICES Name of Committee: Center for Scientific Review Special Emphasis Panel, Dating Violence and Marketing. Date: November 13, 2012. Time: 1:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Anna L Riley, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3114, MSC 7759, Bethesda, MD 20892, 301–435– 2889, rileyann@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: October 24, 2012. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2012–26602 Filed 10–29–12; 8:45 am] National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting [FR Doc. 2012–26565 Filed 10–29–12; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Prospective Grant of Exclusive Evaluation Option License: Pre-clinical Evaluation of Human Therapeutics Utilizing Ubiquitin Based Fusion Proteins With Apoptosis Modifying Proteins Such as BCL–XL Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, Ancillary Studies to the ISC Consortium. Date: November 29, 2012. Time: 3:30 p.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Maria E. DavilaBloom, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 758, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–7637, davilabloomm@extra.niddk.nih.gov. Dated: October 23, 2012. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to practice the inventions covered under the scope of United States Patent No. 6,737,511 issued May 18, 2004 entitled ‘‘Receptormediated Uptake of an Extracellular BCL-xL Fusion Protein Inhibits Apoptosis’’ (HHS Ref. No. E–073–1999/ 0–US–02; Inventors Richard Youle et al.) and International Patent Application No. PCT/US2012/032762 filed April 9, 2012 entitled ‘‘Ubiquitin Fusions for Improving the Efficacy of Cytosolic Acting Targeted Toxins’’ (HHS Ref. No. E–150–2011/0–PCT–02; Inventors Christopher Bachran et al.) to Medicenna Therapeutics, (‘‘MEDICENNA’’) a Canada based company. The patent rights in this invention have been assigned to the government of the United States of America. The prospective exclusive evaluation option license territory may be worldwide and the field of use may be limited to the pre-clinical evaluation of lead therapeutic candidates for the development of human therapeutics within the field of cancer and neurological diseases. Upon expiration or termination of the exclusive evaluation option license, MEDICENNA will have the right to execute an exclusive patent commercialization license which will supersede and replace the exclusive evaluation option license with no broader territory than granted in the exclusive evaluation option license and the field of use will be commensurate with the commercial development plan at the time of conversion. [FR Doc. 2012–26603 Filed 10–29–12; 8:45 am] DATES: (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) BILLING CODE 4140–01–P BILLING CODE 4140–01–P VerDate Mar<15>2010 13:17 Oct 29, 2012 Jkt 229001 National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 SUMMARY: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 14, 2012 will be considered. E:\FR\FM\30OCN1.SGM 30OCN1

Agencies

[Federal Register Volume 77, Number 210 (Tuesday, October 30, 2012)]
[Notices]
[Page 65698]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-26603]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.
    Name of Committee: National Institute of Diabetes and Digestive and 
Kidney Diseases Special Emphasis Panel, Ancillary Studies to the ISC 
Consortium.
    Date: November 29, 2012.
    Time: 3:30 p.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Maria E. Davila-Bloom, Ph.D., Scientific Review 
Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 
758, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7637, 
davila-bloomm@extra.niddk.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and 
Hematology Research, National Institutes of Health, HHS)

    Dated: October 23, 2012.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-26603 Filed 10-29-12; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.